Group 1 - The core viewpoint of the report is that Nuo Cheng Jian Hua (09969) is expected to achieve revenues of RMB 2.01 billion, RMB 2.06 billion, and RMB 2.56 billion for the years 2025-2027, with net profits of RMB 117 million, RMB 17 million, and RMB 188 million respectively. The company holds approximately RMB 7.2 billion in cash and equivalents, which is sufficient for innovative research. The company is driven by scientific innovation and has strong product capabilities. A DCF model gives a target price of HKD 16.81, indicating a potential upside of 28% from the current price [1] Group 2 - The company focuses on hematological malignancies, solid tumors, and autoimmune diseases. The drug Oubutini has shown excellent performance in the SLE IIb trial, with a SRI-4 response rate of 57.1% in the 75mg group, significantly higher than the placebo group at 34.4%. In subgroups with baseline BILAG≥1A or ≥2B, the response rate improved by 35%, and in those with BILAG≥1A or ≥2B and SLEDAI-2K score ≥4, it improved by 43%. The CDE has approved the initiation of a Phase III clinical trial for Oubutini in SLE, with the first patient expected to be enrolled in Q1 2026 [2] Group 3 - The product pipeline is advancing rapidly, with the new TYK2 inhibitor ICP-488 approved for Phase II clinical trials for cutaneous lupus erythematosus (CLE). ICP-488 specifically binds to the TYK2 JH2 domain, blocking the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons. The NMPA has approved the company's Zolbetin (ICP-723) for treating adult and adolescent patients with NTRK fusion gene-positive solid tumors, showing excellent clinical data with an objective response rate of 89.1% and a disease control rate of 96.4%. The 24-month PFS is 77.4%, and the 24-month OS is 90.8%, outperforming first-generation TRK inhibitors. The Phase III registration trial for Oubutini in immune thrombocytopenia (ITP) has completed patient enrollment, with plans to submit a new drug application in the first half of 2026 [3] Group 4 - The company has made significant progress in business development, reaching an agreement with Zenas Bio Pharma in October 2025. Zenas has been granted rights for Oubutini for non-oncological indications outside Greater China and Southeast Asia, as well as for multiple sclerosis globally. Zenas will pay a cash upfront of USD 100 million. The total potential value of this transaction exceeds USD 2 billion, and the collaboration with Zenas will significantly accelerate the overseas clinical development of products [4]

Core Viewpoint - Guoyuan International expects Nuo Cheng Jianhua (09969) to achieve revenues of RMB 2.01 billion, 2.06 billion, and 2.56 billion for the years 2025-2027, with net profits of RMB 117 million, 17 million, and 188 million respectively. The company holds approximately RMB 7.2 billion in cash and equivalents, sufficient for innovative research. The company is driven by scientific innovation and has strong product capabilities. A DCF model gives a target price of HKD 16.81, indicating a potential upside of 28% from the current price [1]. Group 1 - Acalabrutinib shows excellent performance in SLE IIb trials, with a SRI-4 response rate of 57.1% in the 75mg group, significantly higher than the placebo group at 34.4%. In subgroups with baseline BILAG≥1A or ≥2B, the response rate improved by 35%, and in those with BILAG≥1A or ≥2B and SLEDAI-2K score ≥4, it improved by 43%. The CDE has approved the initiation of Phase III clinical trials for Acalabrutinib in SLE, with the first patient expected to be enrolled in Q1 2026 [2]. Group 2 - The company has accelerated its product pipeline, with the new TYK2 inhibitor ICP-488 approved for Phase II clinical trials for cutaneous lupus erythematosus (CLE). ICP-488 specifically binds to the TYK2 JH2 domain, blocking the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons. The NMPA has approved the company's Entrectinib (ICP-723) for treating adult and adolescent patients with NTRK fusion gene-positive solid tumors, showing high objective response rates (89.1%) and disease control rates (96.4%), with a 24-month PFS of 77.4% and OS of 90.8%, outperforming first-generation TRK inhibitors. Acalabrutinib's Phase III registration trial for immune thrombocytopenia (ITP) in China has completed patient enrollment, with plans to submit a new drug application in H1 2026 [3]. Group 3 - The company has made significant progress in business development, reaching an agreement with ZenasBio Pharma in October 2025. Zenas has been granted rights for Acalabrutinib for non-oncology indications outside Greater China and Southeast Asia, as well as global rights for multiple sclerosis; IL-17i rights are granted for regions outside Greater China and Southeast Asia, and global rights for CNS TYK2i. Zenas will pay a cash upfront of USD 100 million, with the total potential value of the deal exceeding USD 2 billion, which will significantly accelerate the overseas clinical development of products [4].

Core Insights - China's contribution to global innovative drug development has significantly increased, with the number of innovative drugs in development now accounting for approximately 30% of the global total, up from 4.1% a decade ago [1] - The Chinese pharmaceutical industry has become the second largest globally, with several Chinese companies now among the top 25 pharmaceutical firms worldwide [1] - The industry is experiencing a "quantity and quality transformation," characterized by a divide between leading companies and smaller biotech firms, with business development (BD) transactions becoming a crucial cash flow source [1][2] Industry Growth and Trends - The scale of China's innovative drug research pipeline now represents about one-quarter of the global total, with approximately 3,000 clinical trials conducted annually, placing China among the top in the world [3] - The total amount of outbound licensing for domestic innovative drugs has surpassed $100 billion, doubling compared to 2024, indicating a significant increase in global recognition of Chinese pharmaceutical assets [3] - Major deals, such as the collaboration between Sangamo Therapeutics and Pfizer, have set new records for upfront payments, highlighting the growing value of Chinese biotech in the global market [4] Business Development Models - Various business development models are emerging as Chinese companies expand internationally, including the NewCo model and the Co-Co model, which allow for more flexible asset operations and shared development costs [6][7] - Early-stage biotech firms tend to prefer traditional models with upfront payments and milestone payments to secure cash flow, while more established companies are moving towards collaborative development models [7] Ecosystem and Policy Support - A complete ecosystem is essential for the sustainable development of China's innovative drugs, requiring collaboration across research, clinical transformation, regulatory upgrades, and payment innovations [8] - Recent policy changes, including the establishment of a commercial insurance directory for innovative drugs, aim to enhance payment mechanisms and support for high-value drugs [9][10] - The dual-directory approach in payment systems is expected to create new commercial opportunities, accelerating the approval process for new drugs and increasing sales for specialized treatments [9][10] Future Directions - The next growth areas for outbound licensing are anticipated to focus on ADC/dual antibody combination therapies, GLP-1 related targets in metabolic diseases, and localized processes for cell and gene therapies [5] - The industry is expected to see a diversification of business development models, with the Co-Co model becoming more prevalent among leading companies while still coexisting with traditional licensing models [6][7]

Investment Rating - The industry investment rating is maintained at "Overweight" [5] Core Insights - The approval of four innovative drugs by the National Medical Products Administration (NMPA) on December 15, 2025, marks a significant milestone for the Chinese pharmaceutical industry, indicating a concentrated effort to enhance the efficiency of drug approval processes and support for urgently needed clinical medications [5][7] - The approved drugs demonstrate significant clinical differentiation and market potential, with clear commercial value, such as the innovative anti-influenza drug from Health元, which offers a single-dose administration, addressing existing treatment challenges [7] - The approval process highlights a "stronger gets stronger" trend, where leading companies are recognized not only for individual products but also for their underlying research and commercialization capabilities, reinforcing their market positions [7] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -3.06% over the past month, -9.84% over the past three months, and -7.91% over the past year, while absolute returns were 0.49% for the last month, -7.88% for the last three months, and 9.5% for the last year [3] Investment Highlights - The approval of four innovative drugs signifies a new phase of high-quality development in the pharmaceutical industry, with a more streamlined process from research and evaluation to market entry [7] - The drugs approved have demonstrated strong clinical efficacy, with the TRK inhibitor showing an objective response rate of 89.1%, fulfilling urgent needs in precision oncology [7] - The report suggests focusing on companies that will directly benefit from these approvals, such as Health元, 诺诚健华, and 恒瑞医药, as they represent key players in the market [7]

Core Viewpoint - InnoCare Pharma has received approval for a phase II clinical trial of its TYK2 inhibitor ICP-488 for treating cutaneous lupus erythematosus, marking a significant step in addressing unmet medical needs in autoimmune diseases [1][4]. Company Overview - InnoCare Pharma is a biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with operations in China and the United States [5]. Product Details - ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor that blocks the signal transduction of inflammatory cytokines, potentially offering a new treatment option for autoimmune diseases [2]. - The drug has shown favorable efficacy and safety in a phase II clinical trial for psoriasis, with plans for a phase III study nearing completion [4]. Disease Context - Cutaneous lupus erythematosus (CLE) is a common autoimmune disease characterized by skin lesions, which can progress to systemic lupus erythematosus affecting multiple organs [3].

Core Insights - By 2025, China's innovative pharmaceutical industry is projected to be the second largest globally, with approximately 30% of new drugs in development being from China, and the total amount of licensing agreements for domestic innovative drugs exceeding $100 billion, doubling from 2024 [1] - The Economist highlights that Chinese innovative drugs are at a critical point of globalization, with significant increases in global market share for Chinese pharmaceutical companies, and stock prices of Chinese biotech firms outperforming their US counterparts [1] - The rapid development is attributed to a decade of regulatory reforms, an ecosystem fostering innovation, and the advantages of China's large population and manufacturing capabilities [1] Industry Challenges - Despite impressive growth, the total market capitalization of Chinese biotech companies is only 15% of their US counterparts, with upfront licensing fees typically two-thirds lower than global averages [1] - Some pharmaceutical companies struggle with commercialization capabilities, which limits their potential value realization [1] Value Restructuring - Leading innovative pharmaceutical companies are advancing towards the top of the global value chain, with firms like Kangfang Biotech transitioning from licensing revenue to self-driven commercialization [2] - Companies are focusing on both global product development and building scalable commercialization platforms, which is becoming a core strategy for Chinese biotech firms to evolve into biopharma [2] Global Innovation Landscape - Chinese pharmaceutical companies are shifting from being fast followers to first movers, evidenced by significant business development deals with major international firms [3] - The mRNA technology sector is also seeing growth, with multiple companies advancing clinical trials and product development [3] mRNA Technology Potential - The value of mRNA technology is becoming increasingly evident, with major collaborations and acquisitions highlighting its potential [4] - Companies are pursuing dual strategies of in-licensing and out-licensing innovative assets to establish a strong global presence [4] Commercialization Challenges - The approval rate for new drugs is low, with only about 5% of drugs entering clinical trials successfully reaching the market, and only 20% of those achieving profitability [6] - Successful commercialization is critical for innovative drug companies, as it provides funding for future research and development [7] Market Dynamics - The traditional division of labor in the biopharmaceutical industry is evolving, with biotech companies gaining more negotiating power and opportunities for commercialization [9] - The market is expected to consolidate around platform companies with revenues between $5 billion and $10 billion, with a focus on integrating commercial strategies for innovative drugs [9] Commercialization Strategies - Companies like Cloudtop New Horizon are establishing integrated commercialization systems to enhance product growth and are actively pursuing partnerships to expand their market reach [10] - The company plans to introduce 3-5 significant products annually and aims to achieve substantial revenue growth by 2030 [10] Industry Evolution - The Chinese innovative pharmaceutical industry is undergoing a comprehensive upgrade, reshaping its value structure and positioning itself as a key player in the global biopharmaceutical landscape [11] - This transformation is moving China from a follower to a significant contributor and standard-setter in global biopharmaceutical innovation [11]

Core Insights - By 2025, China's innovative pharmaceutical industry is projected to have a market size ranking second globally, with approximately 30% of innovative drugs in development worldwide [1] - The total amount of foreign licensing for domestic innovative drugs has surpassed $100 billion, doubling compared to 2024 [1] - The shift from a Western-dominated landscape in biopharmaceutical innovation is evident, as Chinese biotech companies have outperformed their U.S. counterparts in stock price growth over the past year [1] Industry Development - The past decade has seen significant reforms in drug regulation, fostering an ecosystem for innovation and facilitating capital flow, supported by China's large population and manufacturing capabilities [1] - Despite impressive growth, challenges remain, including the total market capitalization of Chinese biotech companies being less than 15% of their U.S. counterparts and lower upfront licensing fees [1] Commercialization Strategies - Leading innovative pharmaceutical companies are advancing towards the global value chain, with firms like Kangfang Biotech transitioning from licensing revenue to self-driven commercialization [2] - Companies are focusing on both global product development and establishing scalable commercialization platforms, which is becoming a core strategy for Chinese biotech firms [2] Global Competition - Chinese pharmaceutical companies are transitioning from "fast-followers" to "first movers," evidenced by significant business development deals with major international firms [3] - The emergence of mRNA technology is notable, with several Chinese companies making strides in this area, including clinical trials for mRNA-based vaccines [3][4] Market Dynamics - The commercialization of innovative drugs in China is accelerating, with 56 innovative drugs approved by the National Medical Products Administration in the first eight months of 2025 [6] - Successful commercialization is critical, as only about 5% of drugs entering clinical trials make it to market, and only 20% of those achieve profitability [6] Future Outlook - Companies like CloudTop are aiming to enhance their commercialization capabilities and expand their product pipelines significantly by 2030, with projected revenues exceeding 15 billion yuan [4][11] - The industry is expected to see a consolidation of platform companies with revenues between 5 billion to 10 billion yuan, indicating a shift in the commercialization landscape [9][10]

Group 1 - The core point of the news is that Innovent Biologics has received approval from the National Medical Products Administration (NMPA) to conduct Phase II clinical trials for its novel TYK2 inhibitor ICP-488, aimed at treating Cutaneous Lupus Erythematosus (CLE) [1] - ICP-488 is an oral, highly selective TYK2 allosteric inhibitor that blocks the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons, thereby inhibiting the pathological processes of autoimmune and inflammatory diseases [1] - CLE is a common type of lupus characterized by diverse skin lesions, with some patients potentially progressing to systemic lupus erythematosus affecting internal organs [1] Group 2 - Innovent Biologics is a commercial-stage biopharmaceutical high-tech company focused on the development of novel drugs for malignant tumors and autoimmune diseases [2] - The company has multiple new drug products at various stages of commercialization, clinical trials, and preclinical development [2] - Innovent Biologics has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [2]

本文源自：金融界AI电报 港股生物医药概念股回升，荣昌生物(09995.HK)涨超2%，泰格医药(03347.HK)、诺诚健华(09969.HK)、 科伦博泰生物-B(06990.HK)、百济神州(06160.HK)等个股跟涨。 ...

北京商报讯（记者 王寅浩 宋雨盈）12月23日，诺诚健华宣布，公司自主研发的新型TYK2抑制剂ICP- 488治疗皮肤型红斑狼疮获国家药品监督管理局药品审评中心批准开展II期临床试验。 据悉，ICP-488是一款口服的高选择性TYK2变构抑制剂，通过特异性结合TYK2 JH2结构域，阻断IL- 23、IL-12和I型干扰素等炎性细胞因子的信号转导，从而抑制自身免疫性疾病和炎症性疾病的病理过 程。 ...